CAR-T cell therapy for B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to treatment, and aims to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell cancer that has returned or not responded to standard treatment, or you have a high-risk large B-cell lymphoma and have just completed 2 cycles of first-line treatment.
- You are generally well enough to carry out daily activities (performance status 0 or 1).
- You have at least one tumor that can be measured.
- You have not had CAR-T therapy before (for the main groups).
- You have not had gene therapy using a lentiviral vector before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.